Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In contrast, the companys Zepbound, as well as diabetes equivalent Mounjaro, is a dual receptor agonist, targeting only GLP-1 and GIP
Administration is typically subcutaneous, with careful dosing and cycling to avoid receptor desensitization and adverse metabolic effects
With Zepbound's targeted approach, these challenges become more manageable, enabling long-term weight stabilization
Consideration should be made to stop semaglutide if less than 5% of the initial weight has been lost after 6 months of treatment
Retrieved 18 July 2026
US$ 28.72
US$ 23.44
US$ 29.12
US$ 25.68
